343 related articles for article (PubMed ID: 25349319)
21. The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age.
Caorsi R; Lepore L; Zulian F; Alessio M; Stabile A; Insalaco A; Finetti M; Battagliese A; Martini G; Bibalo C; Martini A; Gattorno M
Arthritis Res Ther; 2013 Feb; 15(1):R33. PubMed ID: 23442610
[TBL] [Abstract][Full Text] [Related]
22. [An approach to the patients with cryopyrin-associated periodic syndrome (CAPS) : a new biologic response modifier, canakinumab].
Yokota S; Kikuchi M; Nozawa T; Kizawa T; Kanetaka T; Miyamae T; Mori MA; Nishikomori R; Takata H; Heike T; Hara T; Imagawa T
Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(1):23-9. PubMed ID: 22374439
[TBL] [Abstract][Full Text] [Related]
23. Canakinumab for treatment of cryopyrin-associated periodic syndrome.
Feist E; Burmester GR
Expert Opin Biol Ther; 2010 Nov; 10(11):1631-6. PubMed ID: 20955115
[TBL] [Abstract][Full Text] [Related]
24. Detection of a novel mutation in NLRP3/CIAS1 gene in an Indian child with Neonatal-Onset Multisystem Inflammatory Disease (NOMID).
Nair SB; Chavan PP; Athalye AS; Aksentijevich I; Khubchandani RP
Clin Rheumatol; 2019 Feb; 38(2):403-406. PubMed ID: 30066283
[TBL] [Abstract][Full Text] [Related]
25. A somatic NLRP3 mutation as a cause of a sporadic case of chronic infantile neurologic, cutaneous, articular syndrome/neonatal-onset multisystem inflammatory disease: Novel evidence of the role of low-level mosaicism as the pathophysiologic mechanism underlying mendelian inherited diseases.
Aróstegui JI; Lopez Saldaña MD; Pascal M; Clemente D; Aymerich M; Balaguer F; Goel A; Fournier del Castillo C; Rius J; Plaza S; López Robledillo JC; Juan M; Ibañez M; Yagüe J
Arthritis Rheum; 2010 Apr; 62(4):1158-66. PubMed ID: 20131270
[TBL] [Abstract][Full Text] [Related]
26. Successful resolution of stromal keratitis and uveitis using canakinumab in a patient with chronic infantile neurologic, cutaneous, and articular syndrome: a case study.
Hirano M; Seguchi J; Yamamura M; Narita A; Okanobu H; Nishikomori R; Heike T; Hosokawa M; Morizane Y; Shiraga F
J Ophthalmic Inflamm Infect; 2015 Dec; 5(1):34. PubMed ID: 26590045
[TBL] [Abstract][Full Text] [Related]
27. Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians.
Kuemmerle-Deschner JB; Haug I
Ther Adv Musculoskelet Dis; 2013 Dec; 5(6):315-29. PubMed ID: 24294305
[TBL] [Abstract][Full Text] [Related]
28. Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes.
Church LD; McDermott MF
Expert Rev Clin Immunol; 2010 Nov; 6(6):831-41. PubMed ID: 20979548
[TBL] [Abstract][Full Text] [Related]
29. Muckle-Wells syndrome effectively treated with canakinumab: is the recommended dosing schedule mandatory?
Mueller SM; Itin P; Haeusermann P
Dermatology; 2011; 223(2):113-8. PubMed ID: 21967869
[TBL] [Abstract][Full Text] [Related]
30. Delayed reactivation of chronic infantile neurologic, cutaneous, articular syndrome (CINCA) in a patient with somatic mosaicism of CIAS1/NLRP3 gene after withdrawal of anti-IL-1 beta therapy.
Paloni G; Pastore S; Tommasini A; Lepore L; Taddio A
Clin Exp Rheumatol; 2015; 33(5):766. PubMed ID: 26316056
[No Abstract] [Full Text] [Related]
31. [Report of a child with neonatal-onset multisystem inflammatory disease and review of the literature].
Guan N; Li B; Wu Y
Zhonghua Er Ke Za Zhi; 2014 Dec; 52(12):932-6. PubMed ID: 25619352
[TBL] [Abstract][Full Text] [Related]
32. Early canakinumab therapy for the sensorineural deafness in a family with Muckle-Wells syndrome due to a novel mutation of NLRP3 gene.
Iida Y; Wakiguchi H; Okazaki F; Nakamura T; Yasudo H; Kubo M; Sugahara K; Yamashita H; Suehiro Y; Okayama N; Hashimoto K; Iwamoto N; Kawakami A; Aoki Y; Takada H; Ohga S; Hasegawa S
Clin Rheumatol; 2019 Mar; 38(3):943-948. PubMed ID: 30338413
[TBL] [Abstract][Full Text] [Related]
33. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes.
Kuemmerle-Deschner JB; Hachulla E; Cartwright R; Hawkins PN; Tran TA; Bader-Meunier B; Hoyer J; Gattorno M; Gul A; Smith J; Leslie KS; Jiménez S; Morell-Dubois S; Davis N; Patel N; Widmer A; Preiss R; Lachmann HJ
Ann Rheum Dis; 2011 Dec; 70(12):2095-102. PubMed ID: 21859692
[TBL] [Abstract][Full Text] [Related]
34. Severe cryopyrin-associated periodic syndrome first characterized by early childhood-onset sensorineural hearing loss - Case report and literature review.
Hui A; Johnson LB; Greemberg R; Penney L; Ramsey SE
Int J Pediatr Otorhinolaryngol; 2019 May; 120():68-72. PubMed ID: 30772614
[TBL] [Abstract][Full Text] [Related]
35. Rapid and Sustained Long-Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin-Associated Periodic Syndrome Ages Five Years and Younger.
Brogan PA; Hofer M; Kuemmerle-Deschner JB; Koné-Paut I; Roesler J; Kallinich T; Horneff G; Calvo Penadés I; Sevilla-Perez B; Goffin L; Lauwerys BR; Lachmann HJ; Uziel Y; Wei X; Laxer RM
Arthritis Rheumatol; 2019 Nov; 71(11):1955-1963. PubMed ID: 31161734
[TBL] [Abstract][Full Text] [Related]
36. Cryopyrin-associated periodic syndromes: diagnosis and management.
Miyamae T
Paediatr Drugs; 2012 Apr; 14(2):109-17. PubMed ID: 22335455
[TBL] [Abstract][Full Text] [Related]
37. Canakinumab: in patients with cryopyrin-associated periodic syndromes.
Curran MP
BioDrugs; 2012 Feb; 26(1):53-9. PubMed ID: 22168385
[TBL] [Abstract][Full Text] [Related]
38. A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease.
Sibley CH; Chioato A; Felix S; Colin L; Chakraborty A; Plass N; Rodriguez-Smith J; Brewer C; King K; Zalewski C; Kim HJ; Bishop R; Abrams K; Stone D; Chapelle D; Kost B; Snyder C; Butman JA; Wesley R; Goldbach-Mansky R
Ann Rheum Dis; 2015 Sep; 74(9):1714-9. PubMed ID: 24906637
[TBL] [Abstract][Full Text] [Related]
39. Diagnosis of cryopyrin-associated periodic syndrome: challenges, recommendations and emerging concepts.
Sarrabay G; Grandemange S; Touitou I
Expert Rev Clin Immunol; 2015; 11(7):827-35. PubMed ID: 25979514
[TBL] [Abstract][Full Text] [Related]
40. Long term management of patients with cryopyrin-associated periodic syndromes (CAPS): focus on rilonacept (IL-1 Trap).
Church LD; Savic S; McDermott MF
Biologics; 2008 Dec; 2(4):733-42. PubMed ID: 19707454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
